ORTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orchard Therapeutics's Enterprise Value is $302.52 Mil. Orchard Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-94.41 Mil. Therefore, Orchard Therapeutics's EV-to-FCF for today is -3.20.
The historical rank and industry rank for Orchard Therapeutics's EV-to-FCF or its related term are showing as below:
During the past 7 years, the highest EV-to-FCF of Orchard Therapeutics was 0.73. The lowest was -20.76. And the median was -1.92.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Orchard Therapeutics's stock price is $16.70. Orchard Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.000. Therefore, Orchard Therapeutics's PE Ratio for today is At Loss.
The historical data trend for Orchard Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchard Therapeutics Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | -9.99 | -6.18 | -2.09 | -0.04 | 0.47 |
Orchard Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-FCF | Get a 7-Day Free Trial | 0.24 | 0.47 | -0.06 | -0.20 | -1.04 |
For the Biotechnology subindustry, Orchard Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Orchard Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Orchard Therapeutics's EV-to-FCF falls into.
Orchard Therapeutics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 302.516 | / | -94.41 | |
= | -3.20 |
Orchard Therapeutics's current Enterprise Value is $302.52 Mil.
Orchard Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchard Therapeutics (NAS:ORTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Orchard Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 16.70 | / | -4.000 | |
= | At Loss |
Orchard Therapeutics's share price for today is $16.70.
Orchard Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Orchard Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Bobby Gaspar | director, officer: See Remarks | ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Peter Kolchinsky | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Steven Altschuler | director | MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
Jon Ellis | director | ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU |
Plc Glaxosmithkline | director, 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Marc Dunoyer | director | ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU |
John T Curnutte | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Mark Rothera | director, officer: See Remarks | C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
James A Geraghty | director | C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139 |
Alicia Secor | director | 33 HAYDEN AVE., LEXINGTON MA 02421 |
From GuruFocus
By Marketwired • 08-02-2023
By PRNewswire • 10-05-2023
By Marketwired • 09-18-2023
By Business Wire • 11-28-2023
By Value_Insider Value_Insider • 12-12-2022
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 02-10-2023
By Marketwired • 08-03-2023
By Stock market mentor Stock market mentor • 02-08-2023
By GuruFocus Research • 11-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.